IP Verse

Use Of C-Type Natriuretic Peptide Variants To Treat Skeletal Dysplasia

Patent No. EP3328416 (titled "Use Of C-Type Natriuretic Peptide Variants To Treat Skeletal Dysplasia") was filed by Biomarin Pharmaceutical on Aug 1, 2016. The application was issued on Mar 13, 2024.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GRAF VON STOSCH PATENTANWALTSGESELLSCHAFTDec 13, 2024LEPTHIEN
SANDOZDec 12, 2024TER MEER STEINMEISTER & PARTNER
TEVA PHARMACEUTICALSDec 12, 2024KRAUS & LEDERER PARTGMBB

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3328416

BIOMARIN PHARMACEUTICAL
Application Number
EP16750584A
Filing Date
Aug 1, 2016
Status
Granted And Under Opposition
Feb 9, 2024
Publication Date
Mar 13, 2024
External Links
Slate, EP3328416B1, Google Patents